** Shares of biopharma company Edgewise Therapeutics EWTX.O fall as much as 9.7% to a near two-month low of $12.15
** EWTX says its experimental drug showed sustained disease stabilization, up to three years, in a mid-stage study to treat two types of rare genetic disorders
** Becker and Duchenne muscular dystrophies are genetic disorders that affect muscles, causing progressive muscle wasting over time
** FDA found the mid-stage study data insufficient for accelerated approval, but said the measure of physical abilities in Becker muscular dystrophy is a valid main goal for a traditional approval - EWTX
** J.P.Morgan says FDA findings data insufficient for accelerated approval is in line with its expectations
** "We continue to remain positive on EWTX but for the most part still see the cardiovascular assets driving the most value for the stock in the mid-term" - J.P.Morgan
** Company says it plans to meet the FDA in Q4 of 2025 to discuss late stage study design
** Including session moves, stock down 51.6% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.